scholarly journals Adverse Events Costs Associated With Pain Management In Adult Patients With Osteoarthritis And Rheumatoid Arthritis In Five Latin American Countries

2013 ◽  
Vol 16 (3) ◽  
pp. A221 ◽  
Author(s):  
J. Mould-Quevedo ◽  
G. Luna-Casas ◽  
L. Garcia-Mollinedo ◽  
A. Rosado-Buzzo
Keyword(s):  
Rheumatoid Arthritis ◽  
Pain Management ◽  
Adverse Events ◽  
Latin American ◽  
Adult Patients ◽  
Latin American Countries

scholarly journals Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars

2021 ◽  
Vol 61 (1) ◽  
Author(s):  
Gabriela Bittencourt Gonzalez Mosegui ◽  
Fernando Antõnanzas ◽  
Cid Manso de Mello Vianna ◽  
Paula Rojas
Keyword(s):  
Rheumatoid Arthritis ◽  
United States ◽  
Latin American ◽  
United States Of America ◽  
Purchasing Power Parity ◽  
The United States ◽  
Power Parity ◽  
Drug Prices ◽  
The Us ◽  
Latin American Countries

Abstract Background The objective of this paper is to analyze the prices of biological drugs in the treatment of Rheumatoid Arthritis (RA) in three Latin American countries (Brazil, Colombia and Mexico), as well as in Spain and the United States of America (US), from the point of market entry of biosimilars. Methods We analyzed products authorized for commercialization in the last 20 years, in Brazil, Colombia, and Mexico, comparing them to the United States of America (USA) and Spain. For this analysis, we sought the prices and registries of drugs marketed between 1999 and October 1, 2019, in the regulatory agencies’ databases. The pricing between countries was based on purchasing power parity (PPP). Results The US authorized the commercialization of 13 distinct biologicals and four biosimilars in the period. Spain and Brazil marketed 14 biopharmaceuticals for RA, ten original, four biosimilars. Colombia and Mexico have authorized three biosimilars in addition to the ten biological ones. For biological drug prices, the US is the most expensive country. Spain’s price behavior seems intermediate when compared to the three LA countries. Brazil has the highest LA prices, followed by Mexico and Colombia, which has the lowest prices. Spain has the lowest values in PPP, compared to LA countries, while the US has the highest prices. Conclusion The economic effort that LA countries make to access these medicines is much higher than the US and Spain. The use of the PPP ensured a better understanding of the actual access to these inputs in the countries analyzed.

AB0306 Employment and Quality of Life Among Patients with Rheumatoid Arthritis in Four Latin-American Countries

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 996.1-996
Author(s):  
R.M. Xavier ◽  
J. Morales-Torres ◽  
D.C.R. Ramos-Remus ◽  
P. Chalem ◽  
J.F. Molina ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Latin American ◽  
Latin American Countries

PMS22 Work Productivity in Rheumatoid Arthritis Patients from Two LATIN American Countries Treated with Tofacitinib or Biological Dmards

2021 ◽  
Vol 24 ◽  
pp. S142
Author(s):  
Ardila M Gutierrez ◽  
Sanchez JM Reyes ◽  
H. Madariaga ◽  
T. Lukic ◽  
de Leon D Ponce
Keyword(s):  
Rheumatoid Arthritis ◽  
Latin American ◽  
Work Productivity ◽  
Biological Dmards ◽  
Latin American Countries

scholarly journals Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America

2021 ◽  
Vol 7 (4) ◽  
pp. 205521732110615
Author(s):  
Ricardo Alonso ◽  
Aníbal Chertcoff ◽  
Felisa del V Leguizamón ◽  
Lorna Galleguillos Goiry ◽  
Maria B Eizaguirre ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Latin American ◽  
Adenovirus Vector ◽  
Cross Sectional Study ◽  
Serious Adverse Events ◽  
Cross Sectional ◽  
Web Based ◽  
Patient Organizations ◽  
Latin American Countries

Background To date, there are no data available on the safety of COVID-19 vaccines in Latin American patients with Multiple Sclerosis (MS). Objective Characterize safety of COVID-19 vaccines in Latin American (LATAM) patients with Multiple Sclerosis (pwMS). Methods A cross-sectional study between February 1, 2021, and April 30, 2021. Individuals with MS from LATAM countries were invited to participate in a self-administered web-based survey, through MS patient organizations from the region. Results 393 vaccinated pwMS from 10 different Latin American countries were included. The vaccines administered were: inactivated virus vaccines (IVV) in 38.2% of patients, adenovirus vector vaccines (AdV) in 48.8% and mRNA vaccines 13%. All patients received at least one dose of any of the COVID-19 vaccines and 123 (31.3%) declared receiving a second dose. Mean (SD) age 41.5 (11.8) years, 82.4% female, MS disease duration: 8.4 (8.2) years. No serious adverse events were reported with any of the COVID-19 vaccines after either the first or second dose. A lower frequency of adverse events was found with IVV (22%) in comparison with AdV (46.4%) and mRNA (35.3%) ( p < 0.01). Five participants reported having an MS relapse after IVV first dose. Conclusion COVID-19 vaccines applied in LATAM proved safe for MS patients.

scholarly journals Frequency of ambulatory care adverse events in Latin American countries: the AMBEAS/PAHO cohort study

2015 ◽  
Vol 27 (1) ◽  
pp. 52-59 ◽  
Author(s):  
D. Montserrat-Capella ◽  
M. Suarez ◽  
L. Ortiz ◽  
J. J. Mira ◽  
H. G. Duarte ◽  
...  
Keyword(s):  
Cohort Study ◽  
Adverse Events ◽  
Ambulatory Care ◽  
Latin American ◽  
Latin American Countries

scholarly journals Systematic review of the use of low-dose ketamine for analgesia in the emergency department

CJEM ◽  
2017 ◽  
Vol 20 (1) ◽  
pp. 36-45 ◽  
Author(s):  
Gauri Ghate ◽  
Eric Clark ◽  
Christian Vaillancourt
Keyword(s):  
Emergency Department ◽  
Pain Management ◽  
Adverse Events ◽  
Analgesic Effect ◽  
Low Dose ◽  
Adult Patients ◽  
Quality Data ◽  
Treatment Recommendation ◽  
Kappa Statistics ◽  
Rescue Analgesia

AbstractObjectivesThe aim of the study is to determine the performance of low-dose ketamine (LDK) as an analgesic for acute pain management in adult patients in the emergency department (ED).MethodsWe systematically reviewed electronic databases, grey literature, conference abstracts, and clinical trial registries. Two independent reviewers identified eligible studies. These selections were subsequently reviewed by one reviewer who identified the final eligible studies, using refined inclusion and exclusion criteria. Our outcome measures included the analgesic effect of LDK, need for rescue analgesia, and neuropsychological adverse events secondary to LDK use. We assessed inter-rater agreement using kappa statistics and proposed a treatment recommendation using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) software. Heterogeneity among studies precluded meta-analysis.ResultsOur electronic search identified 1,408 records; 44 were selected for full evaluation (kappa=0.70), and 8 were included after the final review. All six randomized controlled trials and two observational studies were set in the ED where LDK was administered to adult patients ( >18 years old) exclusively for pain management. All studies had an overall low risk of bias. There was extensive variation in the dose and route of LDK used (0.1-0.7 mg/kg SC/IV/IM), administration protocols, and use of adjunct analgesia. Overall, most studies reported a significant analgesic effect of LDK with occasional need for rescue analgesia and mild-to-moderate adverse events (dizziness, dysphoria, and confusion).ConclusionThere are moderate to low quality data supporting LDK as an alternative analgesic in the ED with the potential for minimal requirement of rescue analgesia and self-limited neuropsychological adverse events.

Prevalence of adverse events in the hospitals of five Latin American countries: results of the 'Iberoamerican study of adverse events' (IBEAS)

2011 ◽  
Vol 20 (12) ◽  
pp. 1043-1051 ◽  
Author(s):  
J. M. Aranaz-Andres ◽  
C. Aibar-Remon ◽  
R. Limon-Ramirez ◽  
A. Amarilla ◽  
F. R. Restrepo ◽  
...  
Keyword(s):  
Adverse Events ◽  
Latin American ◽  
Latin American Countries

scholarly journals Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study

2020 ◽  
Author(s):  
Qiang Wang ◽  
Haipeng Guo ◽  
Yu Li ◽  
Xiangdong Jian ◽  
Xinguo Hou ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Adverse Events ◽  
Hospital Discharge ◽  
Discharge Rate ◽  
Standard Of Care ◽  
Adult Patients ◽  
Controlled Study ◽  
Open Label ◽  
Randomized Clinical Study

ABSTRACTOBJECTIVETo evaluate the safety and efficacy of leflunomide for the treatment of refractory COVID-19 in adult patients.DESIGNOpen-label controlled studySETTINGA designated hospital for patients with refractory COVID-19 in Wuhan, China.PARTICIPANTS27 hospitalized adult patients (≥18 years of age) with radiologically confirmed pneumonia and SARS-CoV-2 positive for more than 28 days despite standard care were assigned to receive standard of care (SOC, grp I) or leflunomide + SOC (grp 2). After 2 weeks, grp 1 and grp 2 patients who continued to be SARS-CoV-2-positive received leflunomide for 14 days while continuing SOC.MAIN OUTCOME MEASURESThe primary outcomes were the rate of and time to SARS-CoV-2 clearance and the 14-day and 30-day hospital discharge rate.RESULTSTwelve patients enrolled in grp 1 and 15 patients were in grp 2. The 14 days SARS-CoV-2 viral clearance rate was 80.0% (12/15) for grp 2 patients receiving leflunomide versus 16.7% for grp 1 patients (2/12) (P=0.002). By day 14, the median time to SARS-CoV-2 clearance was 6.0 days (range 1-12, IQR 1-12) for grp 2 patients. In grp 1, two patients converted to viral negative on days 1 and 6 (P=0.002). The 14-day discharge rate was 73.3% (11/15) for the grp 2 versus 8.3% (1/12) for grp 1 (P=0.001). The 30-day discharge rate was 100% (15/15) for the grp 2 versus 66.7% (8/12) for grp 1. No severe adverse events or deaths were reported.CONCLUSIONLeflunomide is effective in enhancing SARS-CoV-2 clearance and hospital discharge in refractory COVID-19 patients. The addition of leflunomide to SOC did not increase adverse events versus SOC. These preliminary observations underscore a need for a randomized clinical study of leflunomide in SARS-CoV-2 infection.WHAT IS ALREADY KNOWN ON THIS TOPICBased on the large numbers of global infected patients of SARS-CoV-2, there will be many patients on persist viral positive which is named refractory covid-19. Specific medication for the treatment of the refractory covid-19 has been approved.Leflunomide has been widely used in rheumatoid arthritis and psoriatic arthritis with good safety and tolerance. Recently, it is found an activity of anti-SARS-CoV-2 in vitro and the effective concentration of leflunomide is within the recognized therapeutic level for rheumatoid arthritis.WHAT THIS STUDY ADDSLeflunomide is effective in enhancing SARS-CoV-2 clearance and hospital discharge in refractory COVID-19 patients. The safety and tolerability of the 14-28-day course of treatment with leflunomide is acceptable.

Sign in / Sign up

Export Citation Format

Share Document